[Skip to content]

Cancer Advice - from leading UK Cancer Specialists
Find information
.

Imatinib trials prove successful

University of Texas MD Anderson Cancer Center in Houston

Chronic myeloid leukaemia (CML) patients who are unresponsive to conventional treatments could be given imatinib in the future.


A new report from the University of Texas MD Anderson Cancer Center in Houston has found that the targeted drug can be very effective, as 93 per cent of CML sufferers who use the gene-inhibiting medicine survive at least eight years. Without imatinib, the average survival span is only three to six years.


The scientists state these results show most patients can benefit from imatinib use after unsuccessful interferon treatments and other therapeutic options do not always have to be considered.


However, doctors warned that despite the successes, little is known about the long-term prognosis of patients who receive the drug.


Cancer Research UK states that CML is split into three stages. In the chronic and accelerated phase, symptoms include tiredness, weight loss and an enlarged spleen, in the blast phase symptoms develop rapidly and patients begin to feel unwell. 

© Adfero Ltd

 

Cancer treatment news : 28 February 2012

 

Get an opinion from a leading UK cancer specialist

Our online medical opinion service provides you with expert advice on treatment options from one of our leading cancer specialists. Complete the form for a response within 24 hours.

Ask for advice

 

Find a cancer specialist

Search our online database of private cancer specialists across the UK, or select one of our featured oncologists and cancer specialists.

Find a specialist